# AllerFund

> AllerFund is a VC fund in Scarsdale backing Health Care, Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Scarsdale, United States
- Total investments: 12
- Last investment: Sep 2025
- Lead investor: 17%
- Last updated: Aug 2026
- Website: https://www.allerfund.com/home

AllerFund is a VC fund in Scarsdale focused on Health Care and Biotechnology. AllerFund they provides treatments, diagnostics, and products for children and adults with developing food allergies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 50% |
| Biotechnology | 4 | 33% |
| Medical | 3 | 25% |
| Life Science | 2 | 17% |
| Sensor | 1 | 8% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Seed | 3 | 25% |
| Venture - Series Unknown | 2 | 17% |
| Pre-Seed | 1 | 8% |
| Series B | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 67% |
| Germany | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Anjo.ai | Remote Monitoring, Early Detection and Data-Driven Insights for Life-Threatening Allergies | $610K | Pre-Seed | Sep 01, 2025 |  |
| Moonlight Therapeutics | Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. | $2.4M | Seed | Aug 15, 2024 |  |
| Amulet | Amulet is shining a light on invisible threats in our food system. Amulet has two core brands: - Allergy Amulet helps consumers determine whether their foods are safe by detecting potentially life-threatening allergenic ingredients. - Amulet Scientific equips businesses and manufacturers with tools to help ensure the safety of their food supplychain. Learn more: www.allergyamulet.com www.amuletscientific.com | $5.8M | Series A | Aug 12, 2024 |  |
| Amulet | Allergy Amulet is the world’s smallest and fastest consumer food allergen sensor, testing for common allergenic ingredients in seconds. Whether it’s on a keychain, a necklace, a wristband, or in a pocket, Allergy Amulet’s sleek and portable design allows users to savor life’s important moments, safely and simply. Food allergies affect 32 millionAmericans and between 220-520 million people globally. That’s 1 in 13 children and 1 in 10 adults. Allergy Amulet has the potential to improve the quality of life for the millions of people living with food allergies or intolerances. | $5.8M | Series A | Aug 12, 2024 |  |
| ATANIS Biotech | ATANIS Biotech engages in clinical allergy research and diagnostic assay development. |  |  | Mar 28, 2023 |  |
| ATANIS Biotech | ATANIS Biotech engages in clinical allergy research and diagnostic assay development. |  | Seed | Mar 28, 2023 |  |
| IgGenix | IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade. | $40M | Series B | Feb 06, 2023 |  |
| Alladapt Immunotherapeutics | Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens. | $119M | Venture - Series Unknown | Jun 22, 2022 |  |
| Ready, Set, Food! | Ready, Set, Food! makes it easy for parents reduce their baby's risk of developing peanut, egg, and milk allergies by up to 80% with our gentle, daily system. | $20M | Series A | Jan 01, 2022 |  |
| IgGenix | IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade. | $25M | Series A | Jul 27, 2021 |  |

10 of 12 investments shown.

## Co-investors
- [Great Oaks Venture Capital](https://shizune.co/investors/profile/great-oaks-venture-capital) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [HealthX Ventures](https://shizune.co/investors/profile/healthxventures) — VC Fund, 2 deals together
- [Incite.org](https://shizune.co/investors/profile/incite-org) — VC Fund, 2 deals together
- [iX Life](https://shizune.co/investors/profile/ix-life) — VC Fund, 2 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does AllerFund invest in?

AllerFund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AllerFund last invest?

The most recent investment recorded for AllerFund closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co